Тестостерон и фенугрек

 

Trigonella foenum-graecum (fenugreek)

Six studies (42, 53, 57, 58, 63, 64) were conducted examining the effects of fenugreek seed extracts on testosterone concentrations. Three studies used the Testofen® extract, manufactured by GencorTM (also known as Fenu-FG) (details of extract preparation not provided) (57, 58, 63) and the other 3 studies used the extracts IND9, manufactured by Indus Biotech® (53), Furosap®, manufactured by Chemical Resources (CHERESO) (42), and an extract standardized for Grecunin, manufactured by Indus Biotech® (64) (details of all extract preparations not provided). Five studies were randomized, double-blind, placebo-controlled trials (42, 57, 58, 63, 64) and one was a randomized, double-blind, placebo-controlled crossover study (53). A total of 366 male participants were recruited for the studies, with ages ranging from 18 to 72 y and samples sizes ranging from 16 to 120 participants.

Four of the 6 studies demonstrated increased testosterone concentrations with fenugreek supplementation (42, 53, 58, 64), while 2 studies (57, 63) showed no effect of supplementation (Table 1). Three out of 4 studies also demonstrated positive effects on (calculated) FT (53, 58, 63), and the 2 fenugreek studies that included BT as an outcome measure demonstrated positive effects (53, 64). The acute study by Mokashi et al. (53) recruited 16 healthy men aged between 18 and 45 y (sequence active-placebo (AB): 24.5 ± 5.63 y; sequence placebo-active (BA): 27.62 ± 4.4 y). Participants supplemented with a fenugreek seed extract (IND9), at a daily dosage of 600 mg for 10 h, increased their TT concentrations (IND9: 28.0%; placebo: 5.8%; P = 0.018), calculated FT (cFT) concentrations (IND9: 37.5%; placebo: 15.5%; P = 0.038), and BT (IND9: 33.8%; placebo: 8.8%; P = 0.025). However, there were no between-group differences in the concentration of the directly measured FT (P > 0.05). Two studies (42, 64) recruited healthy, young (18–30 y) men. A fenugreek seed extract, Furosap® (250 mg daily), supplemented for 12 wk was associated with a significant increase in TT concentrations (22.7%) compared with the placebo group (−2.0%) in young men (n = 40; 18–30 y; mean: 24.02 ± 3.9 y) (42), while in 30 healthy men, aged between 18 and 24 y, a fenugreek seed extract (standardized for Grecunin), at a daily dosage of 500 mg, was associated with a significant increase in TT concentrations (6.6%) compared with the placebo group (−13.3%), and a significant increase in BT concentrations (12.3%) compared with the placebo group (−14.3%) after 8 wk of supplementation (64). In a 12-wk study conducted in 120 overweight or obese men, aged between 43 and 70 y (intervention group: 54.8 ± 6.9 y; control group: 56.4 ± 7.4 y), supplementing with 600 mg daily of a specialized fenugreek seed extract, Testofen®, was associated with a significant increase in TT concentrations (12.2%) compared with the placebo group (−6.1%) (P = 0.001) and an increase in cFT concentrations (9.5%) compared with the placebo group (−9.1%) (P = 0.002). There was no statistically-significant difference in SHBG concentrations between the 2 groups (58). The 2 studies that showed no effect of fenugreek supplementation on TT concentrations (57, 63) recruited healthy men, with participants in the Rao and Grant (57) study including men with benign prostate hyperplasia (BPH). In the 8-wk study conducted by Wankhede et al. (63), the researchers examined the effects of a fenugreek seed extract, Fenu-FG, on testosterone concentrations in 60 healthy men aged between 18 and 35 y (intervention group: 23.21 ± 3.73 y; control group: 21.62 ± 3.96 y). A daily dose of 600 mg of the fenugreek seed extract was associated with a significant increase in FT concentrations (98.7%) compared with the placebo group (48.8%) (P < 0.05). However, no significant difference in TT concentrations was found between the groups. In the 12-wk study conducted by Rao and Grant (57) in 100 men with BPH aged between 53 and 72 y (intervention group: 61.8 ± 8.0 y; control group: 64.0 ± 7.7 y), the 12-wk administration of Testofen® (600 mg/d) was associated with no significant difference in any hormone concentrations between the intervention and placebo groups.

Более того, в исследованиях на животных введение 4-гидроксиизолейцина, экстракта из семян пажитника, снижало концентрацию кортизола в сыворотке крови ( 77 )